Global Distribution Access AcuFocus is now part of Bausch + Lomb, which provides a global sales and distribution platform for ophthalmic devices. This enables rapid adoption of IC-8 IOL through established channels among surgeons who already purchase B+L cataract solutions. Propose a joint value proposition featuring IC-8 within B+L premium IOL offerings, with bundled training and after sales support. Potential to reduce time to market in new regions and accelerate scale.

Clinical Network Leverage CorneaGen's acquisition history indicates existing clinical and surgeon relationships that can accelerate IC-8 adoption. Leverage CorneaGen platforms for clinical education, outcomes data, and referral pathways to drive case volumes. Partnerships may include co marketed trials, case studies, and reimbursement evidence to support adoption in specialized settings.

Education Driven Adoption IC-8 has seen product extensions such as new power ranges. There is an opportunity to drive surgeon education around patient selection, indications, and long term outcomes to increase conversions. Develop targeted training programs, workshops, and digital marketing materials to support adoption by surgeons moving from standard IOLs to small aperture solutions.

International Market Expansion IC-8 is CE marked and present in Europe and Asia. The post acquisition pathway with Bausch + Lomb can help expand to additional markets using existing regulatory and distribution capabilities. Focus on regions with aging populations and demand for premium refractive outcomes. Align with local reimbursement strategies and distributor partnerships.

R and D Collaboration Past funding and private equity backing indicate a willingness to invest in innovation. With Bausch + Lomb resources there is potential to co develop next generation small aperture IOLs, expand indications, and accelerate clinical trials. Frame opportunities for joint product development, capital efficiency, and faster commercialization.